About Simris Group
At Simris, we are pioneering the next generation of ADC payloads to revolutionise cancer treatment. Our platform is built on the world’s largest cyanobacterial strain library and over two decades of deep scientific expertise.
Through our proprietary discovery and bioconjugation technologies, we are developing novel, IP-protected payloads with the potential to dramatically improve both the efficacy and safety of ADC therapeutics.
Simris Biologics
Identifying novel natural products and developing technology platforms to turns these into products that transform lives.